Abstract : Biotechnology, rather than defined as a distinct industry like automobiles or steel, is instead a scientific knowledge base --a rapidly evolving technology --that has economically valuable applications in such diverse industries as pharmaceuticals, medical diagnostics, agriculture, bio-environmental remediation and chemical processing. Biotechnology has captured the imagination of ambitious scientific investigators, investors seeking high rates of return, as well as economic development officials who hope to anchor the industry within their district and reap the economic and employment rewards. Biotech is still at an early stage and there are many competing hypotheses about its future development. This paper adapts the concept of the anchor tenant from real estate economics to explore the locational concentration and specialization of the emerging biotech industry. Established Anchor firms who use a new technology may create knowledge externalities that benefit smaller dedicated biotech firms and increase overall innovative output in the region. In the situation of a shopping mall, the market failure is addressed through rents. In the absence of such a transfer mechanism among firms, we may except that smaller firms would benefit from a location premium and this would result in a greater number of new start-ups and better performance.
Introduction
One of the important motivations in economic geography is to understand the forces that contribute to the agglomeration of innovative activity and affect the growth potential of the firms and cities. A significant body of research examines this question and demonstrates the importance of knowledge spillovers (see Feldman 1999 for a recent review). More recent work highlights the importance of industry life cycle (Duranton and Puga 2001) , the composition of activities within an agglomeration (Glaeser et al. 1992; Henderson et al. 1995, Feldman and Audretsch 1999 ) and the effect of existing industrial structure (Klepper 2001; Rosenthal and Strange forthcoming). This work suggests a more nuanced understanding of the nature of agglomeration economies and the way in which the fortunes of firms and regions are intertwined.
Biotechnology, the commercialization of scientific discoveries related to genetic engineering, provides an example of a new industry formed primarily by entrepreneurial startups. The industry has captured the imagination of ambitious scientific investigators, investors seeking high rates of return, as well as government officials who hope to capture the industry's potential economic and employment rewards. Biotech, however, is still at an early stage and there are many competing hypotheses about the nature and direction of its future development.
Biotechnology presents an opportunity to study the emergence and development of a new industry that has a strong science base coupled with great commercial potential. While significant resources are spent trying to promote new firm formation and the development of biotech clusters, we have a limited understanding of the process by which new industries become anchored in a local economy and, as a result, how locations may reap the resulting economic rewards.
This paper uses a panel of firms to explore the locational patterns and place-specific evolution of the in the U.S. biotech industry. As predicted from prior studies of knowledge-intensive industries, the biotech industry is becoming more geographically concentrated and highly specialized in certain locations. While the existence of knowledge externalities contributes to geographic concentration the larger question of how regional specialization is determined and how this affects firm survival and growth and subsequently the viability of the regional cluster is relatively unexplored.
One answer may be that existing firms may serve as anchors that establish skilled labor pools, specialized intermediate industries and provide knowledge spillovers for new technology intensive firms in the region. Established firms may provide expertise and knowledge about specific applications, product markets, and technical developmental trajectories that move generic scientific innovations in a particular direction, which, over time, may distinguish the specialization of the industrial cluster. For example, if there is a regional anchor with a sophisticated expertise in vaccines, new start-up firms may be likely to specialize in that trajectory. Once the region is noted to have developed an expertise, others that work on the application or in the product market may be encouraged to start firms in the region. Over time, a cluster develops around a specialized expertise. This implies a regional path dependency that stems from the existence of the anchor firm to the specialization of new firms that enter the industry in that location. As a result, the fortunes of technologies, firms, and regions are jointly determined.
The next section of the paper examines the historical development of the biotech industry. The next section develops the concept of a regional anchor. Section 3 sets out some of the empirical patterns of geographic location and specialization in the biotech industry. Section 4 develops the concept of the Anchor firm as an agglomerative force and provides hypotheses about the Anchors' relationship to the formation of new dedicated biotechnology firms and their growth. Section 5 provides empirical tests of these hypotheses. Section 6 concludes with some reflective conclusions and future areas of research.
Biotechnology as an emerging industry in a regional context
The biotechnology industry is a collection of firms that focus on the application of recombinant DNA (rDNA) and its related technologies. This industry is based on a series of scientific advances in the twentieth century that provided key insights into the biological basis of life (Kenney 1986:9-27) .
1 This technology may be conceptualized as a radical scientific breakthrough that creates a platform for revolutionary economic growth (Rifkin 1999) . Just as our understanding of chemistry in the prior century revolutionized products and production processes in such diverse industries as the dye industry, pharmaceuticals, agriculture and fuel, biotechnology displaces the focus from chemistry to molecular biology in applications across a variety of industries. (Powell and Brantley 1992) and maintain strong ties with academic researchers (Zucker and Darby 1996; Audretsch and Stephan 1996) .
1 Modern biotechnology traces its origins to the discovery of the molecular structure of the basic building block of genetic material, deoxyribonucleic acid or DNA, by James Watson and Francis Crick in the 1950s. This work made it possible to identify the genes that make specific proteins. James Watson and Francis Crick were awarded the Nobel Prize in Medicine in 1962 for this work. See Watson (1981) for an account of the discovery process.
2 Hall et al. (2001) argue that the patent application date should be used to date inventive activity as the lag between application and grant dates reflects administrative policies at the U.S. Patent Office. 3 For example, in licensing the Cohen-Boyer patents on recombinant DNA technology, Stanford University asked for a one-time licensing fee of $10,000 and royalty rates ranging from 0.5% on sales of end products such as insulin to 10% on sales of research vectors and enzymes (Scherer 1999: 55 [ Table 2 about here] headquarters for the pharmaceutical industry. In contrast, Los Angeles and Orange County in Southern California is noted to be the home of Amgen, one of the earliest and currently the world's largest biotech company. 11 Thus, the geographic location of the industry appears to be anchored by some large institutions, related firms and successful early entrants to the industry.
Technological Specialization
Biotechnology is a scientific knowledge base that has economically valuable applications in such diverse industries as pharmaceuticals, medical diagnostics, agriculture, bio-environmental remediation and chemical processing. There is evidence of regional specialization in biotech products and technological sub-fields that suggest there are unique and regionally defined centers of expertise.
[ Table 3 about here]
We analyzed the regional concentration of product categories by city for the cities with the largest number of dedicated biotech firms in Table 3 . For example, Boston, Massachusetts was the site for 142 firms in 1997. Of these 142 firms, 67 firms had an active interest in therapeutics. This represents 42.41 percent of the firms within the city. The location quotient measures the degree of specialization of the firms within a city relative to the nation. 12 A location quotient of 100 indicates that the city has the same proportion of companies specialising in a certain product category as the national industry. In Boston, the location quotient for therapeutics is 155, indicating that the industry concentration in therapeutics is 55 percent greater than if firms 11 Amgen's website (http://www.amgen.com/corporate/AboutAmgen/backgrounder.html) indicates that the company chose Thousand Oaks, California as its location to be near such major research centers as the University of California at Los Angeles, the University of California at Santa Barbara and the California Institute of Technology. 12 It is calculated as the ratio of the percentage of the state's biotech firm with a specific specialization divided by the percentage of the nation's biotech firms with that specialization.
specializing in therapeutics were evenly distributed throughout the country. These results suggest that the industry is developing differentiated and unique capabilities in specific locations.
13
[ Table 4 about here]
In contrast, Table 4 presents location quotients for cities that do not have a prominent presence for the industry overall but exhibit a high degree of specialization. It is most surprising that the cities listed are not typically considered as hot beds for technology and lack many of the prerequisites for science-based industry development, notably prominent research universities. 14 While the term biotechnology is used to describe an entire industry, it is really a set of many different product applications in the categories noted above. Following the path of most generic platform technologies, genetic engineering DNA replication and the other scientific techniques that define biotechnology are adapted to specific commercial uses. While market
forces will decide what applications are pursued, we may expect that a geographic pattern of technology specialization reflects the localized nature of knowledge spillovers. Existing expertise in a region may define the transformation of generic scientific discoveries into specific specialized technological trajectories. Orlando (2000) and Autant-Bernard (2001) provide evidence that the ability to benefit from knowledge spillovers is conditioned on technological proximity: the effects of knowledge spillovers are greater for similar applications. This suggests 13 These data are based on firms' reports of their research and product development areas. No measure of firm effort or success in these fields is provided.
14 These firms are included in the BioAbility database have a product development agenda in biotechnology and are potential clients for firms who use the U.S. Company Database as a marketing tool.
that firms working on applications for which the region is specialized will realize a locational premium that will aid their growth.
Most analysis considers biotechnology as a homogeneous industry. Kenney and Von Berg (1999) note that early discussions of the computer industry relied on an aggregation of mainframe computers and personal computers. Yet, in retrospect there was substantial regional differentiation between these two sub-sectors which subsequently manifested in widely divergent growth trajectories. In sum, we may expect that the growth trajectory is endogenous to the technology trajectory. Thus the specific technological tools and the applications the firm develops is a function of regional capability. The growth of the cluster and the region, in turn, may be a function of the technology chosen.
[ Table 5 about here] Table 5 presents more descriptive statistics on the characteristics of dedicated biotechnology firms and the industrial concentrations in the ten most prominent cities. Column 1 provides the average year founded for all the dedicated biotechnology firms, both in terms of mean (with standard deviation) and median. While we date the beginning of the industry to the early 1970s, these data suggest that the industry is in different stages of development in different locations. Column 2 presents average number of employees. Again, there is great variation, reflecting not only the age of firms but also the success of a few dedicated biotech firms. Column 3 presents the fraction of dedicated biotechnology firms that are either publicly traded or subsidiaries of other firms. The number of firms that are independently privately held is the residual fraction.
Differences in Industry Composition
City-industry demographic data are provided for the time period 1997-2001: death rate, the number of firms that failed during the time period relative to the total number of firms in 1997; the merger rate: the number of firms that merged or were acquired over the time period relative to the population, and: the birth rate or the rate at which new firms were started relative to the 1997 existing base of firms.
Finally, the last column in Table 5 • dominated by a large number of new start-up firms dedicated to biotechnology with participation by a number of larger, more established firms; • specialized in terms of product applications; and,
• heterogeneous between clusters with respect to rates of growth in terms of the number of firms, their size, age and type of financial backing.
Descriptive Analysis in Context
Much of the empirical investigation of the biotech industry has focused on academic research and linkages to university activity with mixed results. The work of Zucker and Darby and their co-authors examined the influence of academic star scientists prior to 1990. 16 Toole (forthcoming) notes that the focus on star scientists is due to the observation that biotechnology discoveries are characterized by tacit knowledge that is best communicated through face-to-face contact. They conclude that the location of biotechnology start-ups is influenced by the location of these star scientists. Zucker, Darby and Armstrong (1998: 152) interpret this to suggest that market mechanisms rather than knowledge spillovers account for the geographic concentration of the industry. But, they qualify their conclusions: "We suspect that more or better screens would identify top scientists in other aspects of modern biotechnology, which are not captured by genetic sequence discoveries, and would reduce or even eliminate the separate significance of 15 As noted previously, the Anchor firms are more established firms with product lines that predate the biotechnology revolution but have current efforts involving biotechnology. 16 Biotechnology star scientists are defined as those scientists with more than 40 genetic sequence discoveries in GenBank, the NIH genetic sequence database, through April 1990.
top-quality universities and federally supported university researchers ."
This suggests that the findings may reflect the very beginning of the industry, which coincided with aggressive intellectual property licensing on the part of universities and a series of initiatives to leverage universities for local economic development. We may question the importance of universities to the continuing development of the industry, especially to the progress of specialized commercial applications. Thus while knowledge spillovers from universities may be important to early stage innovative activity, universities alone may not be sufficient to anchor a developing industry in a location. Dasgupta and David (1987) highlight the distinction between the social organization of science and the more practical concerns of technology. Science, the pursuit of new knowledge, occurs primarily within the domain of the research university and is characterized by a prioritybased reward system that emphasizes scientific publication. Technology, on the other hand, develops ideas from science for commercial markets. It is characterized by the pursuit of economic returns and its venue is for-profit firms. While it is appropriate to consider patents, publication and the location of star scientists in the earliest stages of firm formation -the science stage-we may expect that as an industry develops and science is translated into commercial applications the locational dynamics may change to emphasize industrial and technological attributes. While science resources may be most important in the earliest stages of the industry development, technology resources may become more important as the industry develops.
Evidence on the location of the biotech industry highlights the importance of the location of the chemical and pharmaceutical industry, especially their headquarters and R&D labs (Gray and Parker 1998; Orsenigo 2001:81-82; Zeller 2001) . Orsenigo (2001:86) notes, "The preexistence of a strong pharmaceutical national industry, with some large internationalized companies may have been a fundamental prerequisite for the rapid adoption of molecular biology" and further, the strength of the local science base is important but may not be the only factor in accounting for the development of the biotech industry. The biotech industry in Italy developed in Milan which did not have the top-rated academic research while Naples, an important academic center, did not develop a biotech industry (Orsenigo 2001:83) ."
Innovative activity depends on knowledge and knowledge spillovers are geographically mediated. The next step is to understand causal relationships in agglomerations. Given that tacit knowledge resides in industrial firms, it would be useful to consider the role of industrial firms in agglomerations to explain these empirical observations and provide some testable hypothesis. The next section develops a theoretical model to account for these observations.
The Anchor-Tenant Hypothesis
Local economies are geographically bounded collections of firms. The question is, what forces promote the agglomeration of innovative activity and affect growth potential? Insights into agglomerations of firms may borrow from the real estate economics literature, which considers the problem of creating a viable economic unit in the design of the shopping mall (Agrawal and Cockburn 2002) . Shopping malls are freestanding groups of retail stores under one roof, accessible primarily by car. They are designed to be self-contained shopping destinations that are isolated from other retail districts. Surrounded by parking space, they may be seen to resemble cities in their geographic isolation and dispersion throughout the landscape. Cities, like shopping malls, are the result of market forces. However, while it is difficult to observe the forces that shape agglomerations, the shopping mall problem is tractable. The problem for the profit-maximizing real estate developer is to rent space to a set of retail store tenants in order to generate a large volume of consumer foot traffic.
The typical shopping mall configuration is at least one large nationally recognized department store with an established clientele and then a diversified set of smaller, lesser known and more specialized stores. 17 The large national department store is known as the anchor tenant 18 . It is termed the anchor as it generates high volume mall traffic that provides a customer base for the shopping mall (Eppli and Shilling 1995; Pashigian and Gould 1998) . If the anchor leaves the mall, the viability of the smaller stores is threatened (Gatzlaff, Sirmans, and Diskin 1994) .
The anchor tenant's brand recognition creates an externality for the smaller stores who realize greater sales volume than they would in other locations. The value of this externality is reflected in higher rents the average tenant pays in comparison to the rent paid by the anchor tenant. This form of price discrimination reflects a willingness of the average tenants to pay a premium for location in the mall. Of course, capturing the value of externality is difficult but the existence of higher rents per square foot for the average tenant recognizes that a positive externality exists.
A regional economy may similarly benefit from the presence of large, technologically sophisticated entities that anchor local economies. Conceptually, the foot traffic generated in this case would be the volume of ideas. This may have particular importance for small firms in emerging industries which is associated with innovation. An anchor, in the form of a large, established firm may create externalities that contribute to benefit of agglomerations. Other studies have considered large established firms as part of an innovative infrastructure and found that the presence of related industry increases innovative output. In addition, Criscuolo, and
Rajneesh (2002) among others adapt the concept of absorptive capacity to the geographic level to account for the ability of a region to benefit from R&D investments. The anchor tenant hypothesis proposes that a large firm may be a better anchor, in terms of economic success, for a developing industry than an equivalent number of small firms. Even if the stock of skilled employees were equal under each regime, the large firm may exert a stronger influence.
Organizational theorists have long recognized that there are size advantages to task coordination, efficiencies from internal economies of scale and scope and increased information flows. We can apply this theory to a regional economy to demonstrate how it may benefit from the presence of a large firm.
Certainly, the presence of a large established entity creates some of the well-known advantages of agglomeration economies such as pools of skilled labor and demand for specialized inputs that may benefit smaller start-up firms. In addition, an anchor may provide a pool of potential entrepreneurs who may take ideas out of the established anchor and form new firms.
One measure of innovation that is important for early stage emerging industries is start-up firms.
A stylized fact about entrepreneurship is that individuals do not relocate to start firms but instead use existing local contacts and networks to start their firms (Feldman 2001) . This form of locational inertia indicates that regions holding stocks of potential entrepreneurs are more likely to be successful at promoting new firm start-ups and establishing new industries.
H1: The number of new start-up firms will be positively related to the number of anchor tenants in a city.
Anchor firms may further increase the viability of local firms through knowledge externalities. A large part of the knowledge fundamental to the application of a new technology is tacit: its non-codified nature makes it difficult to share without personal contact, direct inquiry and observation. As a result, distinct geographic patterns of firms and resources emerge according to a particular application and specific technology focus. In the case of biotechnology, there are generic technological breakthroughs, such as DNA replication, that define the industry and then a series of distinct patterns of innovative activities arises reflecting the localized nature of knowledge spillovers and industry development. Anchors may serve as customers for new start-up firms and as such may engage in user innovation networks (von Hipple 1994) . Another stylized fact about start-up firms is that rather than rely on external financing or venture capital, start-up firms grow by selling services or engaging in procurement contracts for specialized products (Bhide 2000) . The presence of an anchor may allow start-up firms to find relatively stable product niches that would allow firms to develop. This suggests that regional trajectories would develop.
H2: The technical specialization of the dedicated biotech firms will be positively related to the number of anchor tenants in a city.
The anchor tenant hypothesis suggests greater geographic concentration around anchors and this may vary over the industry life cycle. At the earliest stages of industry development, we may expect that universities and government labs serve as anchors. University patents, through licensing agreements, provide the technological underpinning of many new start-up firms. Much of the existing research has focused on defining the role of star scientists and university patents in the development of biotech. However, not all regions with strong research universities have been able to develop biotech industries. Universities appear to be a necessary but not a sufficient condition for the development of knowledge-intensive industries. The correlation between university research funding and patents, and company start-ups is weak and not statistically significant (cf. Barnes, Mowery and Ziedonis 1997; Siegel, Waldman, and. Link 1999; Raider 1998 ). In addition, there are examples where other referent institutions, such as government labs or large established companies incubated the biotech industry (Gray and Parker; Feldman and Francis 2002) . This evidence suggests that there are underlying reasons why regions are not able to capture the benefits of their local science base, which have nothing to do with the proximity of a research university.
As the industry develops further, we may expect that more established firms focusing on applications related to biotech could serve as anchors. Locations lacking these anchors may be able to generate start-up firms but not be able to retain firms as they grow.
H3: Growth in dedicated biotech firms will be positively related to the number of anchor tenants in a city.
Anchor firms may create knowledge externalities that benefit the agglomeration and increase overall innovative output in the region. In the situation of a shopping mall, the market failure is addressed through rents. In the absence of such a transfer mechanism among firms, we may except that smaller firms would benefit from a location premium and this would result in a greater number of new start-ups and better performance.
Data and Empirical Results
This paper estimates two naive models to test hypothesis one and three. Our unit of observation is the city-industry reflecting the social organization of economic activity (Glaeser et al 1992) . Descriptive statistics are provided in the Appendix.
With event count data, such as new firm births, a highly skewed error distribution is expected because the data are truncated at zero. 19 The number of new firm start-ups is assumed to be a Poisson process. To accommodate unobserved heterogeneity and time-dependence, we use maximum likelihood estimation. While this is a naïve model, it provides evidence of a relationship of Anchor firms to the number of local start-up firms. The results indicate that employment growth in the city-industry is statistically related to the number of Anchor firms in the city. After controlling for city population, the presence of one additional Anchor firm would translate into greater than one percent growth in employment in dedicated biotechnology firms in the city.
Reflective Conclusions
The development of firms within regions is fundamental to our understanding of economic development, technological change, industrial evolution and economic growth. Firms located in geographically bounded knowledge rich environments are expected to realize higher rates of innovation, increased entrepreneurial activity, and increased productivity due to the localized nature of knowledge creation and deployment. This paper has provided an analysis of the development of the biotech industry, demonstrating increased geographic concentration, specialization and differential growth. The paper borrows from literature on real estate economics to offer some hypothesis about the composition of agglomerations. The concept of the Anchor -a large firm that provides both stability and traffic in ideas is related to the number of dedicated biotech start-ups and their growth. While these results are preliminary they suggest that regional industrial structure, product applications and technological orientation matter to innovative activity in an emerging industry. The ability of firms to derive economic value from knowledge is dependent on the firms' capabilities and strategic use of resources but the local 21 Since many dedicated biotech firms are not yet profitable it is not feasible to use data on sales or output. The employment in dedicated biotech firms is the sum of employment in all of the firms in the city. 22 The number of dedicated biotech firms is highly correlated with the dependent variable and is not included.
environment shapes the firm's competencies, ability to absorb and utilize knowledge in the development of new products. Thus, the capabilities of firms and regions weave a tapestry of knowledge creation and commercial success.
The concept of a regional anchor provides a more detailed examination of the forces of agglomeration with implications for the development of emerging industries and regional specialization. In its earliest years, the biotech industry grew up around university star scientists who licensed innovations to companies. Today, there are many initiatives that attempt to build biotechnology clusters around universities using formal technology transfer mechanisms. Yet universities appear not to be a sufficient condition to promote an industrial cluster. Further, as biotechnology moves out of the lab, out of small single technology based start-ups and into new commercial applications, the location dynamics of the industry are evolving. The emphasis on star scientists is based on the observation that biotechnology discoveries are characterized by tacit knowledge that is best communicated through face-to-face contact. There is little doubt that this natural excludability played a role in the evolution of biotechnology, however, it depends on the specific discovery in question and it is likely to hold true for a relatively short period of time as valuable ideas and methods spread quickly (Toole, forthcoming) . Industrial expertise and knowhow are equally relevant and appear to be stickier and less easily transferred. The presence of Anchor firms may affect the specialized development of the industry within a region, a topic that requires further investigation.
………………………………………………………………………. BioAbility creates snapshots of the industry at specific points in time. It is a proprietary database that is market to companies who seek to sell products to the industry or conduct competitive intelligence. It is primarily a marketing tool.
The data do provide a comprehensive list of companies that participate in the industry at a specific point in time. One copy of the U.S. Company Database was purchased in July 1997. Another copy was purchased in July 2001. Company names were matched to create a panel. This simple statement underestimates the difficulty of creating a two-time period panel because this industry is very fluid and many firms change their names, merge or exist the industry. Verifying the data and status of the companies was a time consuming effort.
First, firms were classified as either dedicated biotech firms or Anchors. The criteria for an Anchor was that 1) the company was started before 1970; and 2) the company was a positive revenue stream from non-biotech product lines or 3) the firm was a wholly owned subsidiary or division of a non-biotech company. To reiterate, these firms are included in the BioAbility database have a product development agenda in biotechnology and are potential clients for firms who use the U.S. Company Database as a marketing tool.
For Dedicated Biotech .Firms (DBFs) there were several outcomes: 1.1.1. Firm is in continuous existence 1. These data form the basis of the investigation.
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